Oncaspar® (pegaspargase) (Revised)
Summary
Humana revised its Oncaspar (pegaspargase) prior authorization policy effective January 1, 2018, with the most recent revision on December 17, 2025. The policy clarifies coverage criteria for pegaspargase as part of multi-agent chemotherapy for acute lymphoblastic leukemia (ALL), requires prior authorization, and specifies five clinical exclusions (disease progression on prior Oncaspar, thrombosis history, pancreatitis history, hemorrhagic events history, and elevated bilirubin >10x ULN). Approval duration is 6 months initially and on renewal, subject to clinical review.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.